(19) World Intellectual Property Organization

International Bureau





PCT

(43) International Publication Date 18 September 2003 (18.09.2003)

(51) International Patent Classification:

(21) International Application Number:

PCT/US2003/003120

(22) International Filing Date:

21 February 2003 (21.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/361,948 5 March 2002 (05.03.2002) US

(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BEALS, John, Michael [US/US]; 6710 Bluffridge Parkway, Indianapolis, IN 46278 (US). KUCHIBHOTLA, Uma [IN/US]; 12604 Bent Oak Lane, Indianapolis, IN 46236 (US).

(74) Agents: STEWART, Mark, J. et al.; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, IN 47206-6288 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE

 $\begin{array}{c} \hbox{(10) International Publication Number} \\ \hbox{WO 2003/076567} \quad A3 \end{array}$

(utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- (88) Date of publication of the international search report: 10 May 2007

(15) Information about Correction: Previous Correction:

see PCT Gazette No. 09/2005 of 3 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROLOGOUS G-CSF FUSION PROTEINS

(57) Abstract: The present invention encompasses heterologous fusion proteins comprising a hyperglycsoylated G-CSF analog fused to protein such as albumin and the Fc portion of animmunoglobulin which act to extend the in vivo half-life of the protein compared to native G-CSF. These fusion proteins are particularly suited for the treatment of conditions treatable by stimulation of circulating neutrophils, such as after chemotherapy regimens or in chronic congenitalneutropenia.





INTERNATIONAL SEARCH REPORT

International application No.

PCT/U	TO	13/0	121	20
PUI/I	JOU	13/U	וכי	∠υ

A. CLASSIFICATION OF SUBJECT MATTER IPC(8): A61K 39/00(2007.01); C07K 17/00(2007.01) C07K 19/00(2007.01)						
USPC: 424/134.1,178.1;530/351 According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIELDS SEARCHED						
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/134.1,178.1;530/351						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Sequence search; East; STN.						
C. DOCUMENTS CONSIDERED TO BE RELEVANT	Cd	Relevant to claim No.				
Category * Citation of document, with indication, where a Y US 5,665,863 (YEH et al.) 9 Sept. 1997; Whole doc	appropriate, of the relevant passages	1-51				
Y US 5,665,863 (YEH et al.) 9 Sept. 1997; Whole doc 67, col. 3, lines 1-19, Figure 5	sument, especially col. 2, lines 9-10, 33-	1-51				
Y Halpern et al., AlbugraninTM, a Recombinant Huma Factor (G-CSF) Genetically Fused to Recombinant I Myelopoietic Effects in Mice and Monkeys. Pharma Whole document	1-51					
Y US 5,908,626 (Chang et al.), 1 June 1999. Whole doc., esp. col.1 line 60-67, col. 2 line 10-14		22-38				
Y US 5,776,895 (Alber et al.), 7 July 1998, col. 3, lines 60-66		1-54				
Y US 5,218,092 (Sasaki et al.), 8 June 1993, col5. lines 5-34, col. 10, lines 32-68, col. 11-15, Examples 1-5, ref. example 4, 10		1-51				
Y US Pub. No. 2002/0151488 A1, (Sarkar et al.), 17 October 2002, [0066]-[0068], [0070]- [0073], [0106], [0143], [0181].		1-51				
Further documents are listed in the continuation of Box C.	See patent family annex.					
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of	"T" later document published after the inter date and not in conflict with the applica principle or theory underlying the inven	tion but cited to understand the				
particular relevance "E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the cl considered novel or cannot be consider	aimed invention cannot be ed to involve an inventive step				
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the cl considered to involve an inventive step with one or more other such documents	when the document is taken alone Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being				
"O" document referring to an oral disclosure, use, exhibition or other means	obvious to a person skilled in the art					
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family					
Date of the actual completion of the international search	Date of mailing of the international search	h report				
14 December 2006 (14.12.2006)	20 Jan 71111					
Name and mailing address of the ISA/US	Authorized officer	Authorized officer				
Mail Stop PCT, Attn: ISA/US Commissioner of Patents	Brenda G Brukabath					
P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Telephone No. (571) 272-1600	0,				

Form PCT/ISA/210 (second sheet) (July 1998)

PCT/US03/03120	_

INTERNATIONAL SEARCH REPORT

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
Y	US Pub. No. 2002/0004483 A1, (Nissen et al.), 10 January 2002, [0065], [0084], [0087], [0093], [0116], [0137], [0193]-[0196]	1-51			
Y	US 5,217,881 (PARK LS), 8 June 1993, col. 3, lines 10-38, col.4 lines 55-68, col.5, lines 1-29	1-51			